FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
(NASDAQ: FBLG) Delayed: 0.81 +0.04 (5.19%)
Previous Close $0.77    52 Week High $ 
Open $0.76    52 Week Low $ 
Day High $0.82    P/E N/A 
Day Low $0.75    EPS $ 
Volume 158,133